BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have been given a consensus recommendation of “Moderate Buy” by the six research firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $15.17.

Several equities analysts have recently weighed in on the company. Royal Bank of Canada reissued an “outperform” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Evercore ISI boosted their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. Barclays raised their target price on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Finally, Needham & Company LLC upped their price target on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a report on Monday, January 13th.

Institutional Trading of BioCryst Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. R Squared Ltd acquired a new position in shares of BioCryst Pharmaceuticals in the 4th quarter valued at $48,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in BioCryst Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 1,322 shares in the last quarter. KBC Group NV raised its position in shares of BioCryst Pharmaceuticals by 80.1% in the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock worth $77,000 after acquiring an additional 4,537 shares during the period. Quantinno Capital Management LP purchased a new stake in shares of BioCryst Pharmaceuticals during the 3rd quarter worth about $82,000. Finally, DRW Securities LLC acquired a new stake in shares of BioCryst Pharmaceuticals during the 2nd quarter valued at about $74,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

BCRX opened at $8.01 on Thursday. The company has a 50 day simple moving average of $7.59 and a two-hundred day simple moving average of $7.67. The firm has a market cap of $1.66 billion, a P/E ratio of -13.13 and a beta of 1.76. BioCryst Pharmaceuticals has a 1-year low of $4.03 and a 1-year high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.07). The company had revenue of $117.10 million for the quarter, compared to analysts’ expectations of $113.99 million. The company’s quarterly revenue was up 35.1% compared to the same quarter last year. During the same period last year, the business earned ($0.19) earnings per share. Equities analysts anticipate that BioCryst Pharmaceuticals will post -0.38 earnings per share for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.